Related Experiment Video
Updated: Aug 6, 2026
08:13
Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
Published on: September 30, 2021
Recombinant factor VIIa in paediatric bleeding disorders--a 2006 review
1Department of Pediatrics, University of New Mexico, Albuquerque, NM 87131-0001, and Children's Hospital of Orange County, Orange, CA, USA. pmathew@salud.unm.edu
Summary
Recombinant factor VIIa (rFVIIa) is safe and effective for pediatric bleeding disorders, including hemophilia. Studies show increased use in children for various conditions with no rise in adverse events.
Area of Science:
- Pediatric Hematology
- Hemostasis and Thrombosis
- Pharmacology
Background:
- Recombinant factor VIIa (rFVIIa) has been a treatment for hemophilia bleeding since 1996.
- It is generally safe and effective for hemophilic patients with inhibitors.
- Off-label use of rFVIIa is increasing in various bleeding conditions.
Purpose of the Study:
- To review and summarize studies on rFVIIa use in children.
- To address the role of rFVIIa in both hemophilic and non-hemophilic bleeding conditions in pediatric patients.
- To evaluate the safety and efficacy of rFVIIa in the pediatric population.
Main Methods:
- Literature review of studies on rFVIIa in children.
- Analysis of data regarding administration methods (bolus, continuous infusion) and dosages.
- Examination of reported adverse events in pediatric patients.
Main Results:
- rFVIIa has demonstrated safety and efficacy in most hemophilic patients with inhibitors.
- Limited randomized studies exist for pediatric off-label use.
- Adverse events have not increased in children despite wider use.
Conclusions:
- rFVIIa is a viable treatment option for bleeding in children, including hemophilia.
- Further research, particularly randomized trials, is needed for off-label pediatric indications.
- Current experience suggests a favorable safety profile for rFVIIa in pediatric patients.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:24Disorders of Hemostasis
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...